Opinion
Video
Author(s):
The panel concludes by offering key takeaways on the evolving treatment landscape for BCG-unresponsive non–muscle invasive bladder cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care
Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic
Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease
Durvalumab plus BCG significantly improves DFS in NMIBC
Physical function and frailty measures offer distinct insights in patients with bladder cancer
PEACE-3 data for radium-223/enzalutamide published in Annals of Oncology
Phase 2 trial launches of combination immunotherapy for mCRPC
Study findings highlight gender gaps in oncology authorship and citation
ORIC-944 shows promise in combination with AR inhibitors in mCRPC